News
Hosted on MSN1mon
Amneal and Shilpa introduce Boruzu in US for cancer treatmentAmneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or intravenous administration, offering a ready-to-use option for patients ...
and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV ...
subcutaneous (SC) formulation in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback